Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

10 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

9(52.9%)

Phase 1

5(29.4%)

Phase 2

2(11.8%)

Phase 4

1(5.9%)

17Total

Phase 3(9)

Phase 1(5)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT04239950Phase 3Completed

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Role: lead

NCT04345471Phase 3Completed

A Study of MD-120 in Patients With Depression

Role: lead

NCT03350386Phase 1Completed

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Role: lead

NCT04221217Phase 3Completed

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Role: lead

NCT02746380Phase 3Completed

A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Role: collaborator

NCT03693131Phase 3Completed

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

Role: lead

NCT03006445Phase 3Completed

Study of FYU-981 in Hyperuricemia With or Without Gout

Role: collaborator

NCT03100318Phase 3Completed

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Role: collaborator

NCT03375632Phase 1Completed

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

Role: lead

NCT03306667Phase 1Completed

Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)

Role: lead

NCT03372200Phase 3Completed

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Role: lead

NCT02052895Completed

Utility of Presepsin in Distinguishing Between Sepsis and SIRS

Role: lead

NCT02901366Phase 2Completed

Mass Balance Study of FYU-981

Role: collaborator

NCT03350373Phase 1Completed

Clinical Pharmacology of FYU-981 (Final Formulation)

Role: lead

NCT02357069Phase 3Unknown

A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Role: collaborator

NCT00231738Phase 4Completed

Protective Effect of EPA on Cardiovascular Events

Role: collaborator

NCT01154985Phase 2Completed

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

Role: lead

NCT00960180Phase 1Completed

Study Evaluating Single Ascending Doses of MR1817

Role: lead

All 18 trials loaded